These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23095282)

  • 61. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
    Li S; Kaur PP; Chan V; Berney S
    Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis.
    Spinelli FR; Di Franco M; Metere A; Conti F; Iannuccelli C; Agati L; Valesini G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S67-9. PubMed ID: 25381982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study.
    Bernelot Moens SJ; van der Valk FM; Strang AC; Kroon J; Smits LP; Kneepkens EL; Verberne HJ; van Buul JD; Nurmohamed MT; Stroes ES
    Arthritis Res Ther; 2016 May; 18(1):115. PubMed ID: 27209093
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Hueber W; Tomooka BH; Batliwalla F; Li W; Monach PA; Tibshirani RJ; Van Vollenhoven RF; Lampa J; Saito K; Tanaka Y; Genovese MC; Klareskog L; Gregersen PK; Robinson WH
    Arthritis Res Ther; 2009; 11(3):R76. PubMed ID: 19460157
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B; Stadlmaier E; Mulabecirovic A; Brezinschek R; Tilz G; Demel U; Mueller T; Brickmann K; Graninger WB; Brezinschek HP
    Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
    Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
    Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic inhibition of tumor necrosis factor-α with infliximab improves myocardial deformation in parallel with aortic elasticity in rheumatoid arthritis.
    Ay B; Vural MG; Ertem AG; Çağırcı G; Akdemir R; Efe TH; Keskin G; Yeter E
    Turk Kardiyol Dern Ars; 2015 Mar; 43(2):138-48. PubMed ID: 25782118
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
    Bibbo C; Goldberg JW
    Foot Ankle Int; 2004 May; 25(5):331-5. PubMed ID: 15134615
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of rheumatoid arthritis: etanercept a recent advance.
    Halin J
    J Am Acad Nurse Pract; 2000 Oct; 12(10):433-41; quiz 442-4. PubMed ID: 11930442
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biological and clinical effects of anti-TNFalpha treatment.
    Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
    Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
    Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
    J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.